Krishna Institute of Medical Sciences Limited Business Intelligence Report
Krishna Institute of Medical Sciences Limited Business Intelligence Report
Executive Cockpit
Latest Quarterly Earnings Summary
Loading latest quarter…
You're viewing a short preview. The full Business Intelligence Report covers 20+ in-depth sections.
AI Summary
Krishna Institute of Medical Sciences (KIMS) has evolved from a regional Andhra-Telangana player into a dominant multi-state corporate healthcare group. The business demonstrates a high-quality compounding history with a 10-year sales CAGR of 23% and a profit CAGR of 25%. KIMS operates a cluster-based expansion model that focuses on providing tertiary and quaternary care at affordable price points, which has historically yielded industry-leading margins. However, recent financial cycles show a significant shift from an asset-light, cash-surplus state to a heavy capital expenditure phase. This…
Key Changes in FY2026
The business has evolved from a regional player in Hyderabad to a leading multi-disciplinary healthcare group with presence in 2-3 tier cities. KIMS has successfully transitioned its clinical mix toward higher-value quaternary care, including organ transplants and advanced cardiac sciences. The strategy involves acquiring underperforming or mid-sized hospitals and implementing the KIMS operational playbook to improve occupancy and ARPOB. The geographical diversification into Maharashtra marks a significant departure from its home-turf concentration, signaling ambitions for a pan-India footprint. Digital transformation initiatives have been integrated to streamline outpatient volumes and clinical records. This evolution from a single-unit entity to a 4,000+ bed capacity group indicates a…
Management Commentary
The management team has demonstrated significant skill in building a regional powerhouse and successfully navigating the public listing process. Communication is transparent, with a high frequency of investor interactions and detailed transcripts that address operational metrics like ARPOB and occupancy. There is a clear strategic focus on 'affordable' super-specialty care, which creates a competitive moat in Tier-2 and Tier-3 cities. However, the recent 1.62% decrease in promoter holding and a slight decrease in overall promoter stake (from 38.8% to 32.5% over three years) requires monitoring. The management's ability to integrate new acquisitions and maintain clinical quality during such rapid scaling is the primary execution challenge. Overall, the leadership remains credible, but the…
Financial Highlights
The financial trajectory of KIMS shows two distinct phases: a high-efficiency phase (2020-2022) with OPM peaking at 32%, and an expansionary phase (2023-2026) where margins have normalized to the 19-21% range. Revenue growth remains strong, projected to hit ₹3,905 Cr by 2026, yet the 'Compounded Profit Growth' over the last 3 years is -9%, reflecting the drag of high depreciation and interest from new hospital units. The significant jump in borrowings from ₹257 Cr in 2022 to over ₹4,253 Cr by 2026 indicates aggressive leverage to fund greenfield and brownfield projects. Interest coverage is under pressure as interest costs are projected to rise from ₹22 Cr to ₹202 Cr in just four years. Despite this, the underlying asset base is growing substantially, laying the groundwork for long-term…
Impact Balance
Headwinds Outweigh TailwindsTop 5 Positives
23% 10-year Compounded Sales Growth
High · 74 · GrowthDominant regional leadership in AP and Telangana
High · 69 · Market PositionHigh asset base expansion (7,759 Cr in total assets)
Moderate · 62 · GrowthStrong institutional investor backing (>47%)
Moderate · 49 · GeneralConsistently positive Cash from Operating Activities
Low · 43 · General
Top 5 Negatives
Borrowings surged 15x between 2022 and 2026
Critical · 86 · SolvencyNet Profit declined 32% in the trailing twelve months
High · 76 · ProfitabilityOperating margins contracted by 1,100 bps since 2022
High · 74 · ProfitabilityDeeply negative Free Cash Flow in recent years
High · 72 · Cash FlowZero dividend payout despite reported profits
Moderate · 50 · Management
Inside the Full Intelligence Dossier · 20+ Sections
A preview of what the complete report analyses for this company.
About Krishna Institute of Medical Sciences Limited's Annual Report & Financial Performance
The latest Krishna Institute of Medical Sciences Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Krishna Institute of Medical Sciences Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Krishna Institute of Medical Sciences Limited — Frequently Asked Questions
Explore more Krishna Institute of Medical Sciences Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.